Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

NCT01513174 is registered in ClinicalTrials.gov with Spanish Lung Cancer Group as lead sponsor.

NCT NCT01513174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01513174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Lead sponsor
Spanish Lung Cancer Group
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2011
Completion date
July 31, 2016
Enrollment
186 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer